Sponsor

Mannkind Corporation

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Mannkind Corporation appears in 49 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials49
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

49 shown
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321 · lead sponsor · 2026-02-04
RECRUITING
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesNCT05904743 · lead sponsor · 2023-07-07
COMPLETED
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesNCT05243628 · lead sponsor · 2022-03-31
COMPLETED
Afrezza® INHALE-1 Study in PediatricsNCT04974528 · lead sponsor · 2021-09-29
COMPLETED
Afrezza® Dosing Optimization StudyNCT04849845 · lead sponsor · 2021-04-09
COMPLETED
Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal VolunteersNCT03464864 · lead sponsor · 2018-03-09
COMPLETED
Afrezza Safety and Pharmacokinetics Study in Pediatric PatientsNCT02527265 · lead sponsor · 2017-09-28
COMPLETED
PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)NCT02485327 · lead sponsor · 2015-07-01
COMPLETED
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes MellitusNCT02470637 · lead sponsor · 2015-06-01
COMPLETED
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 DiabetesNCT01544881 · lead sponsor · 2012-03-01
COMPLETED
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes MellitusNCT01451398 · lead sponsor · 2011-11-01
COMPLETED
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment PeriodNCT01445951 · lead sponsor · 2011-09-01
COMPLETED
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166NCT01201928 · lead sponsor · 2010-10-01
TERMINATED
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 InhalerNCT01196104 · lead sponsor · 2010-09-01
TERMINATED
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary DiseaseNCT00642616 · lead sponsor · 2009-03-01
TERMINATED
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation PowderNCT01798914 · lead sponsor · 2008-10-01
NO_LONGER_AVAILABLE
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate IntakeNCT00747006 · lead sponsor · 2008-09-01
TERMINATED
A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmaticsNCT00673621 · lead sponsor · 2008-05-01
COMPLETED
A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy VolunteersNCT00674050 · lead sponsor · 2008-05-01
COMPLETED
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-WeeksNCT00700622 · lead sponsor · 2008-05-01
TERMINATED
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin LisproNCT00662857 · lead sponsor · 2008-04-01
COMPLETED
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusNCT00642538 · lead sponsor · 2008-02-01
COMPLETED
Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal ChallengeNCT00642681 · lead sponsor · 2007-12-01
COMPLETED
A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 DiabetesNCT00570687 · lead sponsor · 2007-09-01
COMPLETED
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney FunctionNCT00626249 · lead sponsor · 2007-08-01
COMPLETED
A 2-Month Safety Follow-Up TrialNCT00741429 · lead sponsor · 2007-05-01
COMPLETED
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesNCT00475371 · lead sponsor · 2007-04-01
COMPLETED
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.NCT00423254 · lead sponsor · 2007-02-01
COMPLETED
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)NCT01021891 · lead sponsor · 2006-07-01
COMPLETED
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and AsthmaNCT00332826 · lead sponsor · 2006-06-01
TERMINATED
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upNCT00309244 · lead sponsor · 2006-02-01
COMPLETED
Efficacy & Safety of Inhaled Insulin in Type 1 DiabetesNCT00308308 · lead sponsor · 2006-02-01
COMPLETED
Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes MellitusNCT00539890 · lead sponsor · 2005-11-01
COMPLETED
Safety of Inhaled Insulin With Type 1 and Type 2 DiabetesNCT00308737 · lead sponsor · 2005-06-01
COMPLETED
A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin GlargineNCT00539396 · lead sponsor · 2005-03-01
COMPLETED
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 DiabetesNCT00332488 · lead sponsor · 2004-12-01
COMPLETED
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 DiabetesNCT00934414 · lead sponsor · 2004-08-01
COMPLETED
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 DiabetesNCT00511732 · lead sponsor · 2004-06-01
COMPLETED
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' TrialNCT00754624 · lead sponsor · 2004-05-01
COMPLETED
Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 DiabetesNCT00511719 · lead sponsor · 2004-02-01
COMPLETED
Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 DiabetesNCT00511602 · lead sponsor · 2003-12-01
COMPLETED
To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.NCT00419302 · lead sponsor · 2003-10-01
COMPLETED
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin DeliveryNCT06880835 · collaborator · 2025-06-05
RECRUITING
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational DiabetesNCT06535789 · collaborator · 2025-05-01
RECRUITING
A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily InjectionsNCT04125082 · collaborator · 2019-02-27
UNKNOWN
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes PatientsNCT03324776 · collaborator · 2017-10-16
COMPLETED
A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium AloneNCT03313960 · collaborator · 2017-10-05
UNKNOWN
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT StudyNCT03143816 · collaborator · 2017-09-30
COMPLETED
Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation SystemNCT01459133 · collaborator · 2013-05-01
WITHDRAWN

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Mannkind Corporation as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
insulin glargine2
insulin lispro2
fluticasone1
treprostinil Inhalation Powder1
insulin glargine RxCUI 274783 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials insulin lispro RxCUI 86009 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials fluticasone RxCUI 41126 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial treprostinil Inhalation Powder RxCUI 2602750 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor42
collaborator7
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.